home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Foundation Medicine

< Previous 1 2 3 Next >

Foundation Medicine and Natera Announce the Launch of FoundationOne®Tracker Personalized Circulating Tumor DNA Monitoring Assay for Investigational Use and Early Access Clinical Use

January 09, 2023

From Foundation Medicine

Via Business Wire

FoundationOne®Liquid CDx Receives FDA Approval as a Companion Diagnostic for Rozlytrek® (entrectinib)

January 04, 2023

From Foundation Medicine

Via Business Wire

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors for Treatment of Non-Small Cell Lung Cancer Patients

December 21, 2022

From Foundation Medicine

Via Business Wire

Foundation Medicine Launches FoundationReport+™, a New Digital Reporting Experience to Streamline Precision Cancer Care

November 14, 2022

From Foundation Medicine

Via Business Wire

Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care

September 21, 2022

From Foundation Medicine

Via Business Wire

Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008

September 12, 2022

From Foundation Medicine

Via Business Wire

Tickers RLAY

Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic Profiling to Advance Cancer Care

September 06, 2022

From Foundation Medicine

Via Business Wire

Initial Analysis of Tumor Profiling From a Prospective Study by Foundation Medicine, Flatiron Health and Genentech Demonstrates Value of Tissue and Liquid Comprehensive Genomic Profiling in Patients with Advanced Non-Small Cell Lung Cancer

August 08, 2022

From Foundation Medicine

Via Business Wire

U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for Rozlytrek® (entrectinib)

June 09, 2022

From Foundation Medicine

Via Business Wire

Foundation Medicine Announces Strategic Collaboration with Arvinas

June 05, 2022

From Foundation Medicine

Via Business Wire

Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision Therapy

June 03, 2022

From Foundation Medicine

Via Business Wire

Foundation Medicine and Collaborators to Share More Than 20 Abstracts Featuring New Data at the 2022 American Society of Clinical Oncology Annual Meeting Highlighting How Molecular Profiling is Helping to Shape the Future of Personalized Cancer Care

May 26, 2022

From Foundation Medicine

Via Business Wire

Foundation Medicine and Collaborators to Share Scientific Advances at AACR22 Reinforcing the Power of Genomic Testing in Precision Cancer Care

April 05, 2022

From Foundation Medicine

Via Business Wire

U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer

March 17, 2022

From Foundation Medicine

Via Business Wire

U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for KEYTRUDA® (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors

February 21, 2022

From Foundation Medicine

Via Business Wire

Foundation Medicine’s ctDNA Monitoring Assay, FoundationOne®Tracker, Granted Breakthrough Device Designation by U.S. Food and Drug Administration

February 15, 2022

From Foundation Medicine

Via Business Wire

Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs

February 09, 2022

From Foundation Medicine

Via Business Wire

FoundationOne®CDx Receives FDA Approval as a Companion Diagnostic for BRAF Inhibitor Therapeutics in Melanoma

December 08, 2021

From Foundation Medicine

Via Business Wire

Foundation Medicine Now an In-Network Provider for Humana Military and Health Net Federal Services

October 28, 2021

From Foundation Medicine

Via Business Wire

Foundation Medicine Appoints Dymeka Harrison as Chief Commercial Officer

October 13, 2021

From Foundation Medicine

Via Business Wire

Foundation Medicine Appoints Mia Levy, MD, PhD as Chief Medical Officer

September 21, 2021

From Foundation Medicine

Via Business Wire

Science 37® and Foundation Medicine Partner to Enable Interventional Home-Based Clinical Trials in Oncology

September 08, 2021

From Foundation Medicine

Via Business Wire

Foundation Medicine Announces Partnership With Epic to Streamline Access to Genomic Insights for Precision Cancer Care

August 26, 2021

From Foundation Medicine

Via Business Wire

Foundation Medicine Appoints Sanket Agrawal as Chief BioPharma Business Officer

August 04, 2021

From Foundation Medicine

Via Business Wire

Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be Used as a Companion Diagnostic for TABRECTA® (capmatinib)

July 15, 2021

From Foundation Medicine

Via Business Wire

FoundationOne®CDx Receives FDA-Approval as a Companion Diagnostic for ALUNBRIG® (brigatinib) to Identify Patients with ALK positive Metastatic Non-Small Cell Lung Cancer

July 01, 2021

From Foundation Medicine

Via Business Wire

Foundation Medicine and Flatiron Health Announce First-of-its-Kind Integration of Genomic Profiling Into OncoEMR®

June 29, 2021

From Foundation Medicine

Via Business Wire

Foundation Medicine Collaborates on Research Published in The New England Journal of Medicine That Identifies Resistance to KRAS Inhibitors and Underscores Need for Novel Therapeutic Strategies

June 24, 2021

From Foundation Medicine

Via Business Wire

Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera

June 08, 2021

From Foundation Medicine

Via Business Wire

Tickers NTRA

New Study Results Presented by Foundation Medicine and Collaborators at ASCO21 on Ancestry-Based Disparities in Prostate Cancer Care Underscore Importance of Equitable Access to Precision Medicine Advances

June 04, 2021

From Foundation Medicine

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com